WO2012021773A1 - Antibodies to il-1beta and il-18, for treatment of disease - Google Patents

Antibodies to il-1beta and il-18, for treatment of disease Download PDF

Info

Publication number
WO2012021773A1
WO2012021773A1 PCT/US2011/047532 US2011047532W WO2012021773A1 WO 2012021773 A1 WO2012021773 A1 WO 2012021773A1 US 2011047532 W US2011047532 W US 2011047532W WO 2012021773 A1 WO2012021773 A1 WO 2012021773A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibodies
disease
cells
human
Prior art date
Application number
PCT/US2011/047532
Other languages
English (en)
French (fr)
Inventor
Menno Van Lookeren Campagne
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Priority to JP2013524239A priority Critical patent/JP2013537539A/ja
Priority to RU2013110844/10A priority patent/RU2013110844A/ru
Priority to BR112013003279A priority patent/BR112013003279A2/pt
Priority to CA2808185A priority patent/CA2808185A1/en
Priority to MX2013001267A priority patent/MX2013001267A/es
Priority to EP11748847.8A priority patent/EP2603525A1/en
Priority to CN2011800493677A priority patent/CN103154032A/zh
Priority to KR1020137006238A priority patent/KR20130100125A/ko
Publication of WO2012021773A1 publication Critical patent/WO2012021773A1/en
Priority to US13/763,896 priority patent/US20130149308A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PCT/US2011/047532 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease WO2012021773A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2013524239A JP2013537539A (ja) 2010-08-13 2011-08-12 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
RU2013110844/10A RU2013110844A (ru) 2010-08-13 2011-08-12 АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
BR112013003279A BR112013003279A2 (pt) 2010-08-13 2011-08-12 “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2808185A CA2808185A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1.beta. and il-18, for treatment of disease
MX2013001267A MX2013001267A (es) 2010-08-13 2011-08-12 ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EP11748847.8A EP2603525A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease
CN2011800493677A CN103154032A (zh) 2010-08-13 2011-08-12 用于疾病治疗的针对IL-1β和IL-18的抗体
KR1020137006238A KR20130100125A (ko) 2010-08-13 2011-08-12 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
US13/763,896 US20130149308A1 (en) 2011-08-12 2013-02-11 Antibodies to il-1beta and il-18, for treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376010P 2010-08-13 2010-08-13
US61/373,760 2010-08-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/763,896 Continuation US20130149308A1 (en) 2011-08-12 2013-02-11 Antibodies to il-1beta and il-18, for treatment of disease

Publications (1)

Publication Number Publication Date
WO2012021773A1 true WO2012021773A1 (en) 2012-02-16

Family

ID=44511598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/047532 WO2012021773A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease

Country Status (9)

Country Link
EP (1) EP2603525A1 (ja)
JP (1) JP2013537539A (ja)
KR (1) KR20130100125A (ja)
CN (2) CN103154032A (ja)
BR (1) BR112013003279A2 (ja)
CA (1) CA2808185A1 (ja)
MX (1) MX2013001267A (ja)
RU (1) RU2013110844A (ja)
WO (1) WO2012021773A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186728A2 (en) * 2013-05-17 2014-11-20 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
US10538585B2 (en) 2014-11-10 2020-01-21 Hoffmann-La Roche Inc. Anti-ANG2 antibodies and methods of use
US10730938B2 (en) 2014-11-10 2020-08-04 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use in ophthalmology
US11259738B2 (en) 2013-03-14 2022-03-01 UNIVERSITé LAVAL Use of electroretinography (ERG) for the assessment of psychiatric disorders
WO2022107001A1 (en) * 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2022269451A1 (en) * 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103554264B (zh) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 针对IL-1β和IL-17A的双特异性抗体及其应用
BR112017009817A2 (pt) * 2014-11-10 2018-02-14 Hoffmann La Roche anticorpos anti-il-1beta e métodos de utilização
CN110251657B (zh) * 2019-06-14 2020-11-17 中山大学 Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用

Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577300A (en) 1897-02-16 Printing-press
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010989A (en) 1975-10-14 1977-03-08 American Hospital Supply Corporation Lockable drawer compartment
EP0003089A1 (fr) 1978-01-06 1979-07-25 Bernard David Séchoir pour feuilles imprimées par sérigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0073657A1 (en) 1981-08-31 1983-03-09 Genentech, Inc. Preparation of hepatitis B surface antigen in yeast
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0307247A2 (en) 1987-09-11 1989-03-15 Genentech, Inc. A method for culturing recombinant cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
WO1990013646A1 (fr) 1989-04-28 1990-11-15 Transgene S.A. Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5143844A (en) 1985-12-13 1992-09-01 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
WO1993004173A1 (en) 1991-08-14 1993-03-04 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
WO1995023865A1 (en) 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
EP0425235B1 (en) 1989-10-25 1996-09-25 Immunogen Inc Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1996030046A1 (en) 1995-03-30 1996-10-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5622700A (en) 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1997026912A2 (en) 1996-01-23 1997-07-31 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
WO1998006248A2 (en) 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
WO1998023761A1 (en) 1996-11-27 1998-06-04 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5770710A (en) 1987-10-30 1998-06-23 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methlytrithio group
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1998051793A1 (en) 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
WO2000029004A1 (en) 1998-11-18 2000-05-25 Peptor Ltd. Small functional units of antibody heavy chain variable regions
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6180401B1 (en) 1994-03-10 2001-01-30 Genentech, Inc. Polypeptide production in animal cell culture
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002051870A2 (en) 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
WO2002092620A2 (en) 2001-05-11 2002-11-21 Amgen, Inc. Peptides and related molecules that bind to tall-1
US6534628B1 (en) 1994-01-14 2003-03-18 Biovitrum Ab Bacterial receptor structures
WO2003031589A2 (en) 2001-10-11 2003-04-17 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003035694A2 (en) 2001-10-24 2003-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
WO2003057134A2 (en) 2001-10-11 2003-07-17 Amgen, Inc. Specific binding agents of human angiopoietin-2
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030236193A1 (en) 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2004026329A1 (en) 2002-09-19 2004-04-01 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2005035572A2 (en) 2003-10-08 2005-04-21 Domantis Limited Antibody compositions and methods
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7189826B2 (en) 1997-11-24 2007-03-13 Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
US20070061900A1 (en) 2000-10-31 2007-03-15 Murphy Andrew J Methods of modifying eukaryotic cells
WO2007106790A2 (en) * 2006-03-15 2007-09-20 Regents Of The University Of Colorado A gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94022C2 (ru) * 2000-02-21 2011-04-11 Апплайд Резеч Системз Арс Холдинг Н.В. Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
DE60137421D1 (de) * 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
AU2007238677B2 (en) * 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
CA2713342A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
US8377429B2 (en) * 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof

Patent Citations (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577300A (en) 1897-02-16 Printing-press
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010989A (en) 1975-10-14 1977-03-08 American Hospital Supply Corporation Lockable drawer compartment
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0003089A1 (fr) 1978-01-06 1979-07-25 Bernard David Séchoir pour feuilles imprimées par sérigraphie
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
EP0073657A1 (en) 1981-08-31 1983-03-09 Genentech, Inc. Preparation of hepatitis B surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5143844A (en) 1985-12-13 1992-09-01 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US5721108A (en) 1987-01-08 1998-02-24 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
EP0307247A2 (en) 1987-09-11 1989-03-15 Genentech, Inc. A method for culturing recombinant cells
US5770710A (en) 1987-10-30 1998-06-23 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methlytrithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990013646A1 (fr) 1989-04-28 1990-11-15 Transgene S.A. Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5416064A (en) 1989-10-25 1995-05-16 Immunogen, Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0425235B1 (en) 1989-10-25 1996-09-25 Immunogen Inc Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993004173A1 (en) 1991-08-14 1993-03-04 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5622700A (en) 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
US6534628B1 (en) 1994-01-14 2003-03-18 Biovitrum Ab Bacterial receptor structures
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
WO1995023865A1 (en) 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US6180401B1 (en) 1994-03-10 2001-01-30 Genentech, Inc. Polypeptide production in animal cell culture
US5767285A (en) 1994-06-03 1998-06-16 American Cyanamid Company Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5877296A (en) 1994-06-03 1999-03-02 American Cyanamid Company Process for preparing conjugates of methyltrithio antitumor agents
US5821333A (en) 1995-03-01 1998-10-13 Genetech, Inc. Method for making heteromultimeric polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5807706A (en) 1995-03-01 1998-09-15 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
WO1996030046A1 (en) 1995-03-30 1996-10-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026912A2 (en) 1996-01-23 1997-07-31 Genentech, Inc. Anti-cd18 antibodies for use against stroke
WO1998006248A2 (en) 1996-08-15 1998-02-19 Leukosite, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
WO1998023761A1 (en) 1996-11-27 1998-06-04 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US20070178552A1 (en) 1997-05-02 2007-08-02 Genentech, Inc. Method for Making Multispecific Antibodies Having Heteromultimeric and Common Components
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1998051793A1 (en) 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7189826B2 (en) 1997-11-24 2007-03-13 Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000029004A1 (en) 1998-11-18 2000-05-25 Peptor Ltd. Small functional units of antibody heavy chain variable regions
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20060025576A1 (en) 2000-04-11 2006-02-02 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
US20070061900A1 (en) 2000-10-31 2007-03-15 Murphy Andrew J Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002051870A2 (en) 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
US20030195156A1 (en) 2001-05-11 2003-10-16 Amgen Inc. Peptides and related molecules that bind to TALL-1
WO2002092620A2 (en) 2001-05-11 2002-11-21 Amgen, Inc. Peptides and related molecules that bind to tall-1
WO2003057134A2 (en) 2001-10-11 2003-07-17 Amgen, Inc. Specific binding agents of human angiopoietin-2
US20030229023A1 (en) 2001-10-11 2003-12-11 Oliner Jonathan Daniel Specific binding agents of human angiopoietin-2
US20030236193A1 (en) 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2003031589A2 (en) 2001-10-11 2003-04-17 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003035694A2 (en) 2001-10-24 2003-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
WO2004026329A1 (en) 2002-09-19 2004-04-01 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005035572A2 (en) 2003-10-08 2005-04-21 Domantis Limited Antibody compositions and methods
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
WO2007106790A2 (en) * 2006-03-15 2007-09-20 Regents Of The University Of Colorado A gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies

Non-Patent Citations (211)

* Cited by examiner, † Cited by third party
Title
"Animal Cell Culture", 1987
"Antibodies: A Practical Approach", 1988, IRL PRESS
"Basic and Clinical Immunology", 1994, APPLETON & LANGE, pages: 71
"Cell and Tissue Culture: Laboratory Procedures", August 1993, J. WILEY AND SONS
"Cell Biology: A Laboratory Notebook", 1998, ACADEMIC PRESS
"Current Protocols in Immunology", 1991
"Current Protocols in Immunology", 1994, JOHN WILEY & SONS, INC.
"Current Protocols in Immunology", vol. 1-2, 1991, WILEY-INTERSCIENCE
"Current Protocols in Molecular Biology", 2003
"Gene Transfer Vectors for Mammalian Cells", 1987
"Handbook of Experimental Immunology"
"Methods in Molecular Biology", HUMANA PRESS
"Monoclonal Antibodies: A Practical Approach", 2000, OXFORD UNIVERSITY PRESS
"Oligonucleotide Synthesis", 1984
"PCR 2: A Practical Approach", 1995, ACADEMIC PRESS, INC., article "Methods in Enzymology"
"PCR: The Polymerase Chain Reaction", 1994
"Remington's Pharmaceutical Sciences 16th edition", 1980
"Short Protocols in Molecular Biology", 1999, WILEY AND SONS
"The Antibodies", 1995, HARWOOD ACADEMIC PUBLISHERS
"Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOR LABORATORY PRESS
ABBAS ET AL.: "Cellular and Mol. Immunology", 2000, article "An antibody may be part of a larger fusion molecule, formed by covalent or non-covalent association of the antibody with one or more other protein or peptide"
ALMAGRO, FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633
AREND, W.P., G. PALMER, C. GABAY.: "IL-1, IL-18, and IL-33 families of cytokines", IMMUNOL REV., vol. 223, 2008, pages 20 - 38
AZZONI ET AL., J. IMMUNOL., vol. 161, 1998, pages 3493
BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684
BALDASSANO, R.N. ET AL.: "Association of the T300A non-synonymous variant of the A TG 16L gene with susceptibility to paediatric Crohn's disease", GUT., vol. 56, 2007, pages 1171 - 1173
BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BERG ET AL., PNAS (USA, vol. 88, 1991, pages 4723
BIOTECHNOL APPL BIOCHEM., vol. 50, June 2008 (2008-06-01), pages 97 - 112
BLOOM ET AL., PROTEIN SCIENCE, vol. 6, 1997, pages 407 - 415
BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86
BOSTROM ET AL., SCIENCE, vol. 323, 2009, pages 1610 - 1614
BRESSLER, JAMA, vol. 291, 2004, pages 1900 - 1901
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
BRUGGERMANN ET AL., YEAR IN IMMUNO., vol. 7, 1993, pages 33
C. A. JANEWAY, P. TRAVERS, IMMUNOBIOLOGY, 1997
CADWELL ET AL.: "A key role for autophagy and the autophagy gene Atg1611 in mouse and human intestinal Paneth cells", NATURE, vol. 456, 2008, pages 259 - 263
CARTER ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 163 - 167
CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285
CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 - 4289
CARTER ET AL.: "Association of Interleukin-1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population", HUM GENET., vol. 124, 2008, pages 199 - 206, XP019658436, DOI: doi:10.1007/s00439-008-0540-6
CASSEL, S.L., S. JOLY, F.S. SUTTERWALA.: "The NLRP3 inflammasome: A sensor of immune danger signals", SEMIN IMMUNOL., 2009
CERIANI ET AL., CANCER RES., vol. 55, no. 23, 1995, pages 5852S - 5856S
CHAMOW ET AL., J. IMMUNOL., vol. 153, 1994, pages 4268
CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901
CHOTHIA, LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOY ET AL., ARTHRITIS RHEUM, vol. 39, no. 1, 1996, pages 52 - 56
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLYNES ET AL., NATURE MEDICINE, vol. 6, 2000, pages 433 - 446
CLYNES ET AL., PNAS (USA, vol. 95, 1998, pages 652 - 656
DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60
DELALEU NICOLAS ET AL: "Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation.", PERIODONTOLOGY 2000, vol. 35, 2004, pages 42 - 52, XP002661271, ISSN: 0906-6713 *
DEV COMP IMMUNOL, vol. 30, 2006, pages 43 - 56
DHAINAUT ET AL., CRIT. CARE MED., vol. 23, no. 9, 1995, pages 1461 - 1469
DINARELLO C A: "Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 856, 29 September 1998 (1998-09-29), pages 1 - 11, XP002661301, ISSN: 0077-8923 *
DUBOWCHIK ET AL., BIOORG. & MED. CHEM. LETTERS, vol. 12, 2002, pages 1529 - 1532
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
ELLIS ET AL., J. IMMUNOL., vol. 155, no. 2, 1995, pages 925 - 937
FANTUZZI G ET AL: "Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1).", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 19, no. 1, January 1999 (1999-01-01), pages 1 - 11, XP002661272, ISSN: 0271-9142 *
FEBS LETT, vol. 339, 1994, pages 285 - 290
FELLOUSE ET AL., J MOL BIOL, vol. 373, pages 924 - 940
FERRERO-MILIANI, L., O.H. NIELSEN, P.S. ANDERSEN, S.E. GIRARDIN.: "Chronic inflammation: importance of NOD2 and NALP3 in interleukin-lbeta generation", CLIN EXP IMMUNOL., vol. 147, 2007, pages 227 - 235
FLEER ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 968 - 975
GHAZZI ET AL., DIABETES, vol. 46, 1997, pages 433 - 439
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
GRAZIANO ET AL., J. IMMUNOL., vol. 155, no. 10, 1995, pages 4996 - 5002
GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448
HARLOW AND LANE: "Antibodies, A Laboratory Manual, and Animal Cell Culture", 1987
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381
HOUGHTON ET AL., NATURE MEDICINE, vol. 6, 2000, pages 373 - 374
HOURMANT ET AL., TRANSPLANTATION, vol. 58, 1994, pages 377 - 380
HUMPHREYS ET AL., J. IMMUNOL. METHODS, vol. 209, 1997, pages 193 - 202
ISAKOV, N., J. LEUKOC. BIOL., vol. 61, 1997, pages 6 - 16
J. P. MATHER, P. E. ROBERTS: "Introduction to Cell and Tissue Culture", 1998, PLENUM PRESS
JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 3319
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551
JANEWAY ET AL.: "Immuno Biology: The Immune System in Health and Disease", 1999, ELSEVIER SCIENCE LTD., NY. 4TH ED.
JANEWAY: "Immunobiology", 1999, GARLAND PUBLISHING
JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 16, 2006, pages 358 - 362
JHA SUSHMITA ET AL: "The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, vol. 30, no. 47, 24 November 2010 (2010-11-24), pages 15811 - 15820, XP002661303, ISSN: 1529-2401 *
JOHNSON, WU: "Methods in Molecular Biology", vol. 248, 2003, HUMAN PRESS, pages: 1 - 25
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JONES, GENETICS, vol. 85, 1977, pages 12
JURCIC ET AL., CANCER RES, vol. 55, no. 23, 1995, pages 5908S - 5910S
JUWEID ET AL., CANCER RES, vol. 55, no. 23, 1995, pages 5899S - 5907S
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KABAT: "Sequences of Immunological Interest.", 1991, NATIONAL INSTITUTES OF HEALTH
KANNEGANTI THIRUMALA-DEVI: "Central roles of NLRs and inflammasomes in viral infection.", NATURE REVIEWS. IMMUNOLOGY, vol. 10, no. 10, October 2010 (2010-10-01), pages 688 - 698, XP002661304, ISSN: 1474-1741 *
KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34
KIM ET AL., GROWTH FACTORS, vol. 7, 1992, pages 53 - 64
KING ET AL., J. MED. CHEM., vol. 45, 2002, pages 4336 - 4343
KITA ET AL., J. IMMUNOL., vol. 162, 1999, pages 6901
KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOWLURU, R.A. AND S. ODENBACH.: "Role of interleukin-1beta in the pathogenesis of diabetic retinopathy", BR J OPHTHALMOL., vol. 88, 2004, pages 1343 - 1347
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
KRATZ ET AL., CURRENT MED. CHEM., vol. 13, 2006, pages 477 - 523
KUBALLA ET AL.: "Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant", PLOS ONE., vol. 3, 2008, pages E3391
LAMKANFI MOHAMED ET AL: "Inflammasomes: guardians of cytosolic sanctity.", IMMUNOLOGICAL REVIEWS, vol. 227, no. 1, January 2009 (2009-01-01), pages 95 - 105, XP002661270, ISSN: 1600-065X *
LARSEN ET AL.: "Interleukin-1-receptor antagonist in type 2 diabetes mellitus", N ENGL J MED., vol. 356, 2007, pages 1517 - 1526
LEWIS, E.C., A. DINARELLO.: "Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor.", PROC NATL ACAD SCI USA., vol. 103, 2006, pages 16852 - 16857
LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
LITTON ET AL., EUR J. IMMUNOL., vol. 26, no. 1, 1996, pages 1 - 9
LODE ET AL., CANCER RES., vol. 58, 1998, pages 2925 - 2928
LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459
LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125
LORENZ ET AL., J. IMMUNOL., vol. 156, no. 4, 1996, pages 1646 - 1653
LUDWICZEK OTHMAR ET AL: "Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease", EUROPEAN CYTOKINE NETWORK, vol. 16, no. 1, 1 March 2005 (2005-03-01), JOHN LIBBEY EUROTEXT LTD, FR, pages 27 - 33, XP008143999, ISSN: 1148-5493 *
LUDWICZEK, O. ET AL.: "Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease", CLIN EXP IMMUNOL., vol. 138, 2004, pages 323 - 329
LUDWICZEK, O., A. KASER, D. NOVICK, C.A. DINARELLO, M. RUBINSTEIN, H. TILG.: "Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease", EUR CYTOKINE NETW., vol. 16, 2005, pages 27 - 33, XP008143999
MARKS ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 779 - 783
MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
MERCHANT ET AL., J. BIOL. CHEM., vol. 74, 2000, pages 9115
MERCHANT ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 677 - 681
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
MILSTEIN ET AL., NATURE, vol. 537, 1983, pages 3053
MONTELEONE G ET AL: "Bioactive IL-18 expression is up-regulated in Crohn's disease.", JOURNAL OF IMMUNOLOGY, vol. 163, no. 1, 1 July 1999 (1999-07-01), (BALTIMORE, MD. : 1950), pages 143 - 147, XP002661274, ISSN: 0022-1767 *
MONTELEONE, G. ET AL: "Bioactive IL-18 expression is up-regulated in Crohn's disease", J IMMUNOL., vol. 163, 1999, pages 143 - 147
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
NAGY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 829 - 834
NATURE, vol. 341, 1989, pages 544 - 546
NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268
NILSSON ET AL., PROT ENG, vol. 1, 1987, pages 107 - 133
NORD K ET AL., NAT BIOTECH, vol. 15, 1997, pages 772 - 777
NORD K ET AL., PROT ENG, vol. 8, 1995, pages 601 - 608
OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68
O'SULLIVAN ET AL.: "Methods in Enzym.", vol. 73, 1981, ACADEMIC PRESS, article "Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay", pages: 147 - 166
P. FINCH: "Antibodies", 1997
PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498
PANDEY ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 38633
PERRIER, S., F. DARAKHSHAN, E. HAJDUCH.: "IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?", FEBS LETT., vol. 580, 2006, pages 6289 - 6294, XP028061672, DOI: doi:10.1016/j.febslet.2006.10.061
PHYSICIAN'S DESK REFERENCE, 1995, pages 1902 - 1903
PHYSICIAN'S DESK REFERENCE, 1995, pages 2563 - 2565
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 2632
PRESTA ET AL., J. LMMUNOL., vol. 151, 1993, pages 2623
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
PROBA, PLUKTHUN, GENE, vol. 159, 1995, pages 203
PROPST ET AL., J. IMMUNOL., vol. 165, 2000, pages 2214
QUEEN ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
RAVETCH ET AL., ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 492
REYES ET AL., NATURE, vol. 297, 1982, pages 598 - 601
RICHMAN ET AL., CANCER RES., vol. 55, no. 23, 1995, pages 5916S - 5920S
RICKWOOD, D. AND HAMES, B. D.: "Animal Cell Culture: A Practical Approach 2nd Ed.", 1992, OXFORD UNIVERSITY PRESS
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 337
ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618
SAITOH, T. ET AL.: "Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production", NATURE, vol. 456, 2008, pages 264 - 268
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SANDBERG, J.O., A. ANDERSSON, D.L. EIZIRIK, S. SANDLER.: "Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice", BIOCHEM BIOPHYS RES COMMUN., vol. 202, 1994, pages 543 - 548, XP024766331, DOI: doi:10.1006/bbrc.1994.1962
See also references of EP2603525A1 *
SEGAL ET AL., J. IMMUNOL. METHODS, vol. 248, 2001, pages 1 - 6
SHARKEY ET AL., CANCER RES., vol. 55, no. 23, 1995, pages 5935S - 5945S
SHERIFF ET AL., NATURE STRUCT. BIOL., vol. 3, 1996, pages 733 - 736
SHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
SIDHU, S. S., B. LI, Y. CHEN, F.A. FELLOUSE, C. EIGENBROT, G. FUH.: "Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions", J MOL BIOL., vol. 338, 2004, pages 299 - 310, XP004500301, DOI: doi:10.1016/j.jmb.2004.02.050
SIMMONS ET AL., J. IMMUNOL. METHODS, vol. 263, 2002, pages 133 - 147
SIMS ET AL., J. IMMUNOL., vol. 151, 1987, pages 2296
SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
SOMATIC CELL AND MOLECULAR GENETICS, vol. 12, 1986, pages 555
ST JOHN ET AL., CHEST, vol. 103, 1993, pages 932
STEPPE ET AL., TRANSPLANT INTL., vol. 4, 1991, pages 3 - 7
STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39
SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210
TEN HOVE ET AL.: "Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice", GASTROENTEROLOGY., vol. 121, 2001, pages 1372 - 1379, XP005906504, DOI: doi:10.1053/gast.2001.29579
TEN HOVE, T., A. CORBAZ, H. AMITAI, S. ALONI, I. BELZER, P. GRABER, P. DRILLENBURG, S.J. VAN DEVENTER, Y. CHVATCHKO, A.A. TE VELDE: "Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice", GASTROENTEROLOGY., vol. 121, 2001, pages 1372 - 1379, XP002661300 *
TORGOV ET AL., BIOCONJ. CHEM., vol. 16, 2005, pages 717 - 721
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
TREND BIOCHEM SCI, vol. 26, 2001, pages 230 - 235
TRENDS BIOTECHNOL, vol. 21, 2003, pages 484 - 490
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
URLAUB ET AL., PROC. NAT]. ACAD. SCI. USA, vol. 77, 1980, pages 4216
V. T. DEVITA ET AL.: "Cancer: Principles and Practice of Oncology", 1993, J.B. LIPPINCOTT COMPANY
VAN DE VEERDONK FRANK L ET AL: "Inflammasome activation and IL-1[beta] and IL-18 processing during infection.", TRENDS IN IMMUNOLOGY, vol. 32, no. 3, March 2011 (2011-03-01), pages 110 - 116, XP002661302, ISSN: 1471-4981 *
VAN DEN BERG, BIOLTECHNOLOGY, vol. 8, 1990, pages 135
VAN DIJK AND VAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 374
VAUGHAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
VILLANI, AC. ET AL.: "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility", NAT GENET., vol. 41, 2009, pages 71 - 76
VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098
VOLLMERS AND BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 191
VOLLMERS, BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937
W. LOUIS CLEVELAND ET AL., J. IMMUNOL. METHODS, vol. 56, 1983, pages 221 - 234
WATERHOUSE ET AL., NUC. ACIDS. RES., vol. 21, 1993, pages 2265 - 2266
WHEELER RACHEL D ET AL: "Interleukin-18 induces expression and release of cytokines from murine glial cells: interactions with interleukin-1 beta.", JOURNAL OF NEUROCHEMISTRY, vol. 85, no. 6, June 2003 (2003-06-01), pages 1412 - 1420, XP002661273, ISSN: 0022-3042 *
WU ET AL., NATURE BIOTECHNOLOGY, 2007
XU ET AL., IMMUNITY, vol. 13, 2000, pages 37 - 45
YANIV, NATURE, vol. 297, 1982, pages 17 - 18
YANSURA ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOL., vol. 4, 1992, pages 151 - 158
YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062
ZHENG ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 12999
ZHU ET AL., PROTEIN SCIENCE, vol. 6, 1997, pages 781 - 788
ZOLA: "Monoclonal Antibodies: A Manual of Techniques", 1987, CRC PRESS, INC., pages: 47 - 158

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730743B2 (en) 2012-01-13 2023-08-22 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
US11883409B2 (en) 2012-01-13 2024-01-30 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
US11259738B2 (en) 2013-03-14 2022-03-01 UNIVERSITé LAVAL Use of electroretinography (ERG) for the assessment of psychiatric disorders
WO2014186728A3 (en) * 2013-05-17 2015-01-22 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105209643A (zh) * 2013-05-17 2015-12-30 豪夫迈·罗氏有限公司 用于诊断和治疗炎性肠病的方法
JP2016521540A (ja) * 2013-05-17 2016-07-25 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療方法
EP2997162A4 (en) * 2013-05-17 2017-02-01 F. Hoffmann-La Roche AG Methods for diagnosing and treating inflammatory bowel disease
WO2014186728A2 (en) * 2013-05-17 2014-11-20 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US10538585B2 (en) 2014-11-10 2020-01-21 Hoffmann-La Roche Inc. Anti-ANG2 antibodies and methods of use
US10730938B2 (en) 2014-11-10 2020-08-04 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use in ophthalmology
WO2022107001A1 (en) * 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2022269451A1 (en) * 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
CA2808185A1 (en) 2012-02-16
BR112013003279A2 (pt) 2016-06-14
MX2013001267A (es) 2013-04-10
CN103154032A (zh) 2013-06-12
KR20130100125A (ko) 2013-09-09
RU2013110844A (ru) 2014-09-20
JP2013537539A (ja) 2013-10-03
EP2603525A1 (en) 2013-06-19
CN104474546A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
KR102279524B1 (ko) 항-tigit 항체 및 이의 이용 방법
WO2012021773A1 (en) Antibodies to il-1beta and il-18, for treatment of disease
US9975949B2 (en) Anti-CD79b antibodies and methods of use
AU2022231722A1 (en) Humanized and affinity matured antibodies to FcRH5 and methods of use
US8883975B2 (en) Antibodies against IL-18R1 and uses thereof
IL181186A (en) COMPOSITION USEFUL FOR DOWNREGULATING Fc-EPSILON-RI ACTIVITY COMPRISING A BISPECIFIC ANTIBODY OR POLYPEPTIDE THAT CROSSLINKS AN Fc-GAMMA-RIIB RECEPTOR WITH AN Fc-EPSILON-RI-ALPHA- RECEPTOR
US11760797B2 (en) Anti-interleukin-33 antibodies and uses thereof
WO2016008851A1 (en) Anti-il-1b antibodies
US20130149308A1 (en) Antibodies to il-1beta and il-18, for treatment of disease
US20220242944A1 (en) Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180049367.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11748847

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011748847

Country of ref document: EP

Ref document number: MX/A/2013/001267

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013524239

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2808185

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137006238

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013110844

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013003279

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013003279

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130208